Nuveen Asset Management, LLC - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 144 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$3,481,000
+5.3%
915,934
+41.0%
0.00%
+100.0%
Q4 2019$3,306,000
+1.4%
649,525
+0.7%
0.00%0.0%
Q3 2019$3,259,000
-16.8%
644,690
+1.5%
0.00%
-50.0%
Q2 2019$3,918,000635,0150.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q2 2019
NameSharesValueWeighting ↓
Broadfin Capital, LLC 1,583,925$8,007,0001.48%
Phocas Financial Corp. 1,022,708$5,169,0000.55%
RICE HALL JAMES & ASSOCIATES, LLC 1,776,490$8,980,0000.32%
FARALLON CAPITAL MANAGEMENT LLC 7,350,000$37,154,0000.28%
NEXPOINT ASSET MANAGEMENT, L.P. 716,880$3,624,0000.23%
J. Goldman & Co LP 499,698$2,526,0000.19%
PINNACLE ASSOCIATES LTD 1,257,098$6,355,0000.15%
CARILLON TOWER ADVISERS, INC. 3,948,024$19,957,0000.14%
EAGLE ASSET MANAGEMENT INC 4,504,094$22,768,0000.12%
Worth Venture Partners, LLC 32,956$167,0000.10%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders